Biocartis CE-marks Idylla NRAS-BRAF Mutation Test

Biocartis has CE-marked its solid biopsy Idylla NRAS-BRAF Mutation Test. On Thursday, Biocartis said that, together with the CE-marked Idylla KRAS Mutation Test, it can now offers a complete testing for metastatic colorectal cancers (mCRC) for clinical use on its Idylla molecular diagnostics platform.

The ability of Biocartis’ RAS test offering to enable same-day results can now open routes towards faster treatment selection for mCRC patients.

Rudi Pauwels, Chief Executive Officer of Biocartis, commented: “Many of our European customers as well as our distribution partners have been awaiting the CE-mark of our Idylla(TM) NRAS-BRAF Mutation Test. Together with our existing CE-marked Idylla(TM) KRAS Mutation Test for colorectal cancer, which was recently rewarded in a study^[5] by the global pharmaceutical company AstraZeneca as being the fastest, most easy to use and one of the most accurate high precision tests compared to peers, Biocartis now has a full CE-marked colorectal cancer mutations test panel. This panel allows for complete same-day testing and treatment selection for mCRC patients. As such, we expect this CE-marking to add substantial traction to our commercial cartridge consumption.”